Literature DB >> 11956306

Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification.

Natsue Ichizawa1, Takashi Fukutomi, Eriko Iwamoto, Sadako Akashi-Tanaka.   

Abstract

The objectives of this study were to investigate the long-term results of T1a, T1b and T1c Japanese invasive breast cancer patients defined by the UICC classification. The subjects were T1a (38), T1b (256) and T1c (1405) Japanese invasive breast cancer patients. Ten- and 20-year disease-free survival (DFS) and overall survival (OS) rates were analyzed by the UICC T1 subgroups (T1a, T1b, T1c). At 10 years, the respective DFS and OS rates of T1a, T1b and T1c patients were 91.9 and 91.9%, 86.1 and 86.8% and 82.4 and 83.9%, respectively. At 20 years, the respective DFS and OS rates of T1a, T1b and T1c patients were 70.7 and 70.7%, 76.7 and 76.7% and 69.1 and 70.1%. The differences of DFS and OS between T1a and T1c patients were not statistically significant. The DFS of patients with T1c breast carcinoma showed a statistically significant difference from that of T1b patients (p = 0.03). The validation of the T1 subgroup classification in Japanese breast cancer patients was confirmed, particularly for the T1c subgroup.

Entities:  

Mesh:

Year:  2002        PMID: 11956306     DOI: 10.1093/jjco/hyf025

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

1.  Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.

Authors:  G Houvenaeghel; A Goncalves; J M Classe; J R Garbay; S Giard; H Charytensky; M Cohen; C Belichard; C Faure; S Uzan; D Hudry; P Azuar; R Villet; P Gimbergues; C Tunon de Lara; M Martino; E Lambaudie; C Coutant; F Dravet; M P Chauvet; E Chéreau Ewald; F Penault-Llorca; B Esterni
Journal:  Ann Oncol       Date:  2014-01-07       Impact factor: 32.976

2.  T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.

Authors:  Changjun Wang; Ziyuan Chen; Yidong Zhou; Wei Huang; Hanjiang Zhu; Feng Mao; Yan Lin; Yanna Zhang; Jinghong Guan; Xi Cao; Qiang Sun
Journal:  Gland Surg       Date:  2021-03

3.  Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.

Authors:  T Gamucci; A Vaccaro; F Ciancola; L Pizzuti; I Sperduti; L Moscetti; F Longo; M A Fabbri; M A Giampaolo; L Mentuccia; L Di Lauro; P Vici
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

4.  Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer(T1abN0).

Authors:  David Jaraj; Jonas Höijer; Linnea Widman; Johan Ahlgren; Lars-Gunnar Arnesson; Zakaria Einbeigi; Marie Klintman; Eva Vikhe Patil; Malin Sund; Irma Fredriksson; Jonas Bergh; Pettersson Andreas
Journal:  JNCI Cancer Spectr       Date:  2020-09-26

5.  Clinical practice guideline for dedicated breast PET.

Authors:  Makoto Hosono; Tsuneo Saga; Kengo Ito; Shinichiro Kumita; Masayuki Sasaki; Michio Senda; Jun Hatazawa; Hiroshi Watanabe; Hiroshi Ito; Shinichi Kanaya; Yuichi Kimura; Hideo Saji; Seishi Jinnouchi; Hiroyoshi Fukukita; Koji Murakami; Seigo Kinuya; Junichi Yamazaki; Mayuki Uchiyama; Koichi Uno; Katsuhiko Kato; Tsuyoshi Kawano; Kazuo Kubota; Takashi Togawa; Norinari Honda; Hirotaka Maruno; Mana Yoshimura; Masami Kawamoto; Yukihiko Ozawa
Journal:  Ann Nucl Med       Date:  2014-05-31       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.